TY - JOUR
T1 - Burden of illness in not adequately controlled chronic hypoparathyroidism
T2 - Findings from a 13-country patient and caregiver survey
AU - Siggelkow, Heide
AU - Clarke, Bart L.
AU - Germak, John
AU - Marelli, Claudio
AU - Chen, Kristina
AU - Dahl-Hansen, Helen
AU - Glenister, Elizabeth
AU - Bent-Ennakhil, Nawal
AU - Judge, Davneet
AU - Mycock, Katie
AU - Bollerslev, Jens
N1 - Funding Information:
This research was funded by Shire International GmbH, Zug, Switzerland, a member of the Takeda group of companies. Editorial support, funded by Shire International GmbH, a member of the Takeda group of companies, was provided by Afia Akram, PhD, of Complete Healthcare Communications, LLC, a CHC Group company (North Wales, PA, USA).
Publisher Copyright:
© 2019 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Objective: To address knowledge gaps regarding burdens associated with not adequately controlled chronic hypoparathyroidism. Design: Global patient and caregiver survey. Study Populations: Patients with chronic hypoparathyroidism not adequately controlled on conventional therapy and their caregivers. Measurements: Health-related quality of life (HRQoL) and health status were evaluated using the 36-item Short Form version 2 (SF-36 v2.0) and Five-Level EuroQoL 5 Dimensions (EQ-5D-5L) instruments, respectively. Hypoparathyroidism-associated symptoms were assessed by a disease-specific Hypoparathyroidism Symptom Diary and caregiver burden via the Modified Caregiver Strain Index (MCSI). Results: Data were obtained from 398 patients and 207 caregivers. Patients' self-rated hypoparathyroidism-related symptom severity was none (3%), mild (32%), moderate (53%) or severe (12%). Per the Hypoparathyroidism Symptom Diary, patients reported moderate, severe or very severe symptoms of physical fatigue (73%), muscle cramps (55%), heaviness in limbs (55%) and tingling (51%) over a 7-day recall period. Impacts (rated ‘somewhat’ or ‘very much’) were reported by 84% of patients for ability to exercise, 78% for sleep, 75% for ability to work and 63% for family relationships. Inverse relationships were observed between patient self-rated overall symptom severity and HRQoL and health status assessment scores—the greater the symptom severity, the lower the SF-36 and EQ-5D-5L scores. Caregiver burden increased with patient self-rated symptom severity: none, 1.7 MCSI; mild, 5.4 MCSI; moderate, 9.5 MCSI; and severe, 12.5 MCSI. Conclusion: Patients with not adequately controlled hypoparathyroidism reported substantial symptoms and impacts. Greater patient symptom severity was associated with decreased patient HRQoL and health status assessments and increased caregiver burden.
AB - Objective: To address knowledge gaps regarding burdens associated with not adequately controlled chronic hypoparathyroidism. Design: Global patient and caregiver survey. Study Populations: Patients with chronic hypoparathyroidism not adequately controlled on conventional therapy and their caregivers. Measurements: Health-related quality of life (HRQoL) and health status were evaluated using the 36-item Short Form version 2 (SF-36 v2.0) and Five-Level EuroQoL 5 Dimensions (EQ-5D-5L) instruments, respectively. Hypoparathyroidism-associated symptoms were assessed by a disease-specific Hypoparathyroidism Symptom Diary and caregiver burden via the Modified Caregiver Strain Index (MCSI). Results: Data were obtained from 398 patients and 207 caregivers. Patients' self-rated hypoparathyroidism-related symptom severity was none (3%), mild (32%), moderate (53%) or severe (12%). Per the Hypoparathyroidism Symptom Diary, patients reported moderate, severe or very severe symptoms of physical fatigue (73%), muscle cramps (55%), heaviness in limbs (55%) and tingling (51%) over a 7-day recall period. Impacts (rated ‘somewhat’ or ‘very much’) were reported by 84% of patients for ability to exercise, 78% for sleep, 75% for ability to work and 63% for family relationships. Inverse relationships were observed between patient self-rated overall symptom severity and HRQoL and health status assessment scores—the greater the symptom severity, the lower the SF-36 and EQ-5D-5L scores. Caregiver burden increased with patient self-rated symptom severity: none, 1.7 MCSI; mild, 5.4 MCSI; moderate, 9.5 MCSI; and severe, 12.5 MCSI. Conclusion: Patients with not adequately controlled hypoparathyroidism reported substantial symptoms and impacts. Greater patient symptom severity was associated with decreased patient HRQoL and health status assessments and increased caregiver burden.
KW - caregiver
KW - health status
KW - hypoparathyroidism
KW - parathyroid hormone
KW - patient
KW - quality of life
KW - surveys and questionnaires
UR - http://www.scopus.com/inward/record.url?scp=85076406391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076406391&partnerID=8YFLogxK
U2 - 10.1111/cen.14128
DO - 10.1111/cen.14128
M3 - Article
C2 - 31721256
AN - SCOPUS:85076406391
SN - 0300-0664
VL - 92
SP - 159
EP - 168
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 2
ER -